PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith a certificate dated January 04, 2022, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021 PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is to certify that the details of the securities dematerialized during quarter ended 31.12.2021 mentioned above as required by Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 have been furnished to all stock exchanges where the shares of the Company are listed. PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we are enclosing herewith the data of shares dematerialized during the month of December, 2021. PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company from January 01, 2022 till completion of 48 hours from the announcement to the Stock Exchanges regarding Unaudited financial results of the Company for the quarter and nine months ended December 31, 2021. The date of meeting of the Board of Directors to approve the Unaudited financial results of the Company for the quarter and nine months ended December 31, 2021, shall be informed in due course. This is for your kind information and record please. PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we would like to inform you that no share has been dematerialized during the month of November, 2021. Panacea Biotec Ltd - 531349 - Clarification On Movement In Price
We would like to state as under: 1. The Company has made all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 from time to time and has not withheld any material information / announcement that in our opinion would have a bearing on the price / volume behavior in the scrip. 2. As on date, there are no pending information / announcement (including impending announcement) which in our opinion may have a bearing on the price / volume behavior in the scrip. You are requested to take the same on records. Panacea Biotec Ltd - 531349 - Clarification sought from Panacea Biotec Ltd
The Exchange has sought clarification from Panacea Biotec Ltd on December 2, 2021 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. Panacea Biotec Ltd - 531349 - Clarification On News Item Appearing In Times Of India, Mumbai Captioned 'Indiarf, Piramal May Extend Repayment Date For Panacea Debt' And Other Print And Electronic Media On 17.11.2021
We would like to state as under: 1. The Company's WOS, Panacea Biotec Pharma Limited ('PBPL') has issued Series 1A, Series 1B and Series 3 NCDs to Debenture Holders in 2020. 2. The said NCDs were issued pursuant to the structured credit availed by the Company in 2019 and is repayable by April, 2024. While the repayment date of Series 1B and Series 3 NCDs is in April, 2024, the Series 1A NCDs were repayable earlier out of funds from divestment of non-core immovable properties which had got delayed due to the Covid-19 pandemic. 3. The said Series 1A NCDs have partly been redeemed in the past and for balance amount PBPL has got extensions from IndiaRF. We hope to liquidate the said assets soon with the recovery in the real estate market. 4. As on date no amounts are overdue on account of the said Series 1A NCDs. 5. The Company and its WOS, PBPL has sufficient cash flows to take care of its operations and ongoing development programs. You are requested to take the same on records Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated November 12, 2021 for approving the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company for the Quarter and Half year ended September 30, 2021 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the Extract of Statement of aforesaid Unaudited Financial Results published in the following newspapers on November 13, 2021 PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2021
In continuation to our letter dated November 02, 2021 and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 12, 2021, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2021. The same were also reviewed by the Audit Committee in its meeting held earlier on November 12, 2021. The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 05:15 P.M. We request you to kindly bring the above information to the notice of your members.